Corrigendum to: The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients

Aesthet Surg J. 2021 Nov 12;41(12):1494. doi: 10.1093/asj/sjab229.
No abstract available

Publication types

  • Published Erratum

Grants and funding